Transmission electron microscopy and autofluorescence findings in the cornea of diabetic rats treated with aminoguanidine

Canadian Journal of Ophthalmology

Volumn 41, Issue 1, 2006, Pages 60-66

  Yücel, Iclal ^a   Yücel, Gültekin ^a   Akar, Yusuf ^a   Demir, Necdet ^a   Gürbüz, Nilgün ^a   Aslan, Mutay ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Advanced glycosylation end products; Aminoguanidine; Diabetes mellitus; Diabetic keratopathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOFLUORESCENCE; CELL DEGENERATION; CELL ORGANELLE; CELL VACUOLE; CONTROLLED STUDY; CORNEA DISEASE; CORNEA EPITHELIUM; CORNEA STROMA; CYTOPLASM; DIABETES MELLITUS; DIABETIC KERATOPATHY; EVALUATION; HYPERGLYCEMIA; INTRACELLULAR SPACE; MALE; MEASUREMENT; NONHUMAN; PATHOGENESIS; RAT; STREPTOZOCIN DIABETES; TRANSMISSION ELECTRON MICROSCOPY;

EID: 33645127619     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/S0008-4182(06)80068-2     Document Type: Article

References (30)

1. Cisarik-Fredenburg P. Discoveries in research on diabetic keratopathy. Optometry 2001;72:691-704.
2. Azar DT, Spurr-Michaud SJ, Tisdale AS, Gipson IK. Altered epithelial-basement membrane interactions in diabetic corneas. Arch Ophthalmol 1992;110:537-40.
3. Taylor HR, Kimsey RA. Corneal epithelial basement membrane changes in diabetes. Invest Ophthalmol Vis Sci 1981;20: 548-53.
4. Friend J, Ishii Y, Thoft RA. Corneal epithelial changes in diabetic rats. Ophthalmic Res 1982;14:269-78.
5. Kaji Y, Usui T, Oshika T, et al. Advanced glycation end products in diabetic corneas. Invest Ophthalmol Vis Sci 2000;41:362-8.
6. John WG, Lamb EJ. The Maillard or browning reaction in diabetes. Eye 1993;7:230-7.
7. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600.
8. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994;43:676-83.
9. Metz TO, Alderson NL, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch Biochem Biophys 2003;419:41-9.
10. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003;419:89-96.
11. Sell DR, Nelson JF, Monnier VM. Effect of chronic aminoguanidine treatment on age-related glycation, glycoxidation, and collagen cross-linking in the Fischer 344 rat. J Gerontol A Biol Sci Med Sci 2001;56:B405-11.
12. Usta MF, Bivalacqua TJ, Yang DY, et al. The protective effect of aminoguanidine on erectile function in streptozetocin diabetic rats. J Urol 2003;170:1437-42.
13. Ishino Y, Yokoi N, Yasuhara T, et al. Investigation of Corneal Autofluorescence in Diabetic Patients. Jpn J Ophthalmol 2001;45:116.
14. Lowry OH, Rosenbrough NJ, Farr AL, Randell RJ. Protein measurement with folin-phenol reagent J Biol Chem 1951; 193:265-75.
15. Ahmed N, Argirov OK, Minhas HS, Cordeiro CA, Thornalley PJ. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon- (1-carboxyethyl) lysine-modified albumin. Biochem J 2002;364:1-14.
16. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357:593-615.
17. Nyengaard JR, Chang K, Berhorst S, Reiser KM, Williamson JR, Tilton RG. Discordant effects of guanidines on renal structure and function and on regional vascular dysfunction and collagen changes in diabetic rats. Diabetes 1997;46:94-106.
18. Thornalley PJ. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003;419:31-40.
19. Buddi R, Lin B, Atilano SR, Zorapapel NC, Kenney MC, Brown DJ. Evidence of oxidative stress in human corneal diseases. J Histochem Cytochem 2002;50:341-51.
20. Kessel L, Moldow B, van Best JA, Sander B. Corneal autofluorescence in relation to permeability of the blood-aqueous barrier in diabetic patients with clinically significant macular edema and in an age-matched control group. Curr Eye Res 2003;26:307-12.
21. Sato E, Mori F, Igarashi S, et al. Corneal advanced glycation end products increase in patients with proliferative diabetic retinopathy. Diabetes Care 2001;24:479-82.
22. Van Schaik HJ, Alkemade C, Swart W, Van Best JA. Autofluorescence of the diabetic and healthy human cornea in vivo at different excitation wavelengths. Exp Eye Res 1999; 68:1-8.
23. Ishiko S, Yoshida A, Mori F, et al. Corneal and lens autofluorescence in young insulin-dependent diabetic patients. Ophthalmologica 1998;212:301-5.
24. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328-34.
25. Forbes JM, Soulis T, Thallas V, et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 2001; 44:108-14.
26. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A 1991;88:6107-11.
27. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001;50:1636-42.
28. Chen AS, Taguchi T, Sugiura M, et al. Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. Horm Metab Res 2004;36:183-7.
29. Bolton WK, Cattran DC, Williams ME, et al; ACTION I Investigator Group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40.
30. Freedman BI, Wuerth JP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials 1999;20:493-510.